sb 203580 has been researched along with 4-(3-3,4-p-menthadien-(1,8)-yl)olivetol in 1 studies
| Studies (sb 203580) | Trials (sb 203580) | Recent Studies (post-2010) (sb 203580) | Studies (4-(3-3,4-p-menthadien-(1,8)-yl)olivetol) | Trials (4-(3-3,4-p-menthadien-(1,8)-yl)olivetol) | Recent Studies (post-2010) (4-(3-3,4-p-menthadien-(1,8)-yl)olivetol) |
|---|---|---|---|---|---|
| 3,489 | 4 | 1,137 | 27 | 0 | 17 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Clemente, D; Correa, F; Docagne, F; Guaza, C; Mestre, L | 1 |
1 other study(ies) available for sb 203580 and 4-(3-3,4-p-menthadien-(1,8)-yl)olivetol
| Article | Year |
|---|---|
The synthetic cannabinoid WIN 55,212-2 increases COX-2 expression and PGE2 release in murine brain-derived endothelial cells following Theiler's virus infection.
Topics: Animals; Arachidonic Acids; Benzoxazines; Brain; Cell Nucleus; Cell Survival; Chromones; Cyclooxygenase 2; Dinoprostone; Endocannabinoids; Endothelial Cells; Enzyme Activation; Flavonoids; Fluorescent Antibody Technique; Glycerides; Imidazoles; Mice; Microscopy, Confocal; Mitogen-Activated Protein Kinases; Morpholines; Naphthalenes; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Pyridines; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2; Resorcinols; Theilovirus | 2006 |